Xwpharma Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as XW Laboratories Inc. (to 2021)
0
Ending by 2030
Sep 2036
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 4, 2027
- 2 fees due Mar 5 to 26, 2027 · next Mar 5
- 1 fee due Apr 29, 2027The maintenance fee for Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof (US 10,457,627) comes due Apr 29, 2027. Unpaid by Oct 29, 2027, it lapses early.
- 1 fee due Jun 10, 2027The maintenance fee for Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof (US 10,501,401) comes due Jun 10, 2027. Unpaid by Dec 10, 2027, it lapses early.
- 2 fees due Aug 13 to 20, 2027 · next Aug 13
- 1 fee due Sep 12, 2027The maintenance fee for Modified Release Compositions of a Gamma-Hydroxybutyric Acid Derivative (US 11,925,710) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
- 2 fees due Oct 2 to 14, 2027 · next Oct 2
- 2 fees due Nov 5, 2027
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,457,627 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,501,401 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,640,451 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,774,031 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,941,107 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,640,476 | Bicyclic heteroaryl derivatives and preparation and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,882,832 | Bicyclic heteroaryl derivatives and preparation and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,401,249 | Bicyclic heteroaryl derivatives and preparation and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,639,337 | Bicyclic Heteroaryl Derivatives and Preparation and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 10,858,394 | Preparation and uses of reactive oxygen species scavenger derivatives In force · From the USPTO record | In force | From the USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 4 no status recorded